Key points from article :
A new genetic medicine startup, ExcepGen, has emerged from stealth with a mission to "massively expand" the reach of DNA and RNA-based genetic medicines.
The company has developed a new technology that enhances the potency of nucleic acid therapeutics by changing the way cells respond to therapeutic mRNA.
ExcepGen's technology involves encoding a specialised "shield" protein alongside the primary nucleic acid cargo, which improves how cells respond to foreign DNA or RNA and helps prevent negative cell signalling.
The company has secured seed funding totalling $14 million, including a recent investment round.
The new funding will be used to expedite ExcepGen's research and development initiatives, as well as strengthening its collaborative efforts with other companies in the genetic medicine field.
